University of California, San Francisco
Radiology, Medicine, Psychiatry, and Neurology
San Francisco, California
1965 – MD from SUNY Upstate Medical University
1961 – BA from Johns Hopkins University
Dr. Weiner has been doing research for over 40 years and is the Principal Investigator of the Alzheimer’s Disease Neuroimaging Initiative, a 10-year national longitudinal study of over 1500 subjects which is aimed at validating biomarkers for Alzheimer’s disease.
He is also the Principal Investigator of the BrainHealthRegistry.org, an internet based registry with the overall goal of accelerating development of effective treatments for brain diseases. This website registry recruits, screens, and longitudinal monitors brain function on thousands of subjects all over the USA.
His overall research goals are to participate in the development of effective treatments and methods for early detection of Alzheimer’s disease and other brain disorders. In 1980, Dr. Weiner was one of the first investigators to use nuclear magnetic resonance to investigate the metabolism of organs inside a living animal. This technique subsequently became magnetic resonance spectroscopy (MRS).
In 1988, his group used MRS to show that the amino acid N acetyl aspartate (NAA), a marker of healthy nerve cells, is reduced in the epileptic focus in the brain. This marker is now used to help identify the epileptic focus prior to surgery in epilepsy patients.
In 2004, Dr. Weiner’s group reported that reduced NAA predicts development of Alzheimer’s disease in mildly impaired elderly subjects. They have also demonstrated that brain blood flow is reduced in Alzheimer’s disease and in patients with mild impairment.
Dr Weiner has over 750 published articles. In 2006, Dr. Weiner received the William S. Middleton Award, the highest scientific honor bestowed by the Department of Veterans Affairs. In 2010 he was named one of the “Rock Stars of Science”. He also received the Gold Medal of Paul Sabatier University and the City of Toulouse, France.
In 2011 he received the Ronald and Nancy Reagan Research Award from the Alzheimer’s Association. In 2012 he received the Potamkin Award from the American Academy of Neurology and the American Brain Foundation.
DECLARED FINANCIAL INTERESTS
Dr. Weiner is a full time Professor of Medicine, Radiology, Psychiatry, and Neurology for the University of California San Francisco (UCSF), and Principal Investigator of many projects with the above grant funding, including the Brain Health Registry and Alzheimer’s Disease Neuroimaging Initiative (ADNI).
He has served on the Scientific Advisory Boards for Pfizer, BOLT International, Neurotrope Bioscience, Alheon, Inc., Alzheimer’s Therapeutic Research Institute (ATRI), Eli Lilly, U. of Penn’s Neuroscience of Behavior Initiative, National Brain Research Centre (NBRC), India, Dolby Family Ventures, LP, and ADNI. He served on the Editorial Boards for Alzheimer’s & Dementia and MRI
He has provided consulting to Synarc, Pfizer, Janssen, Alzheimer’s Drug Discovery Foundation (ADDF), Neurotrope Bioscience, Avid Radiopharmaceuticals, Clearview Healthcare Partners, Perceptive Informatics, Smartfish AS, Araclon, Merck, Biogen Idec, BioClinica, and Genentech. He holds stock options with Alzheon, Inc.